Author
Listed:
- Cheng-Yuan Li
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan)
- Ying-Xiu Dai
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan)
- Yi-Ju Chen
(School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
Department of Dermatology, Taichung Veterans General Hospital, Taichung 40705, Taiwan)
- Szu-Ying Chu
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan)
- Tzeng-Ji Chen
(School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
Department of Family Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan)
- Chen-Yi Wu
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
Institute of Public Health, National Yang-Ming University, Taipei 11221, Taiwan)
- Chih-Chiang Chen
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan)
- Ding-Dar Lee
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan)
- Yun-Ting Chang
(Department of Dermatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan)
Abstract
Vitiligo is an autoimmune disease characterized by destruction of melanocytes and associated with other autoimmune disease. Whether the dysregulation of immune system enhances oncogenesis or not remains obscure. Until now, no nationwide population-based study has been conducted regarding this. As such, this paper aims to clarify cancer risk in vitiligo patients. A retrospective nationwide population-based cohort study between 2000 and 2010 was performed based on data from the National Health Insurance Research Database of Taiwan. Standardized incidence ratios (SIRs) of cancers were analyzed. Among the 12,391 vitiligo patients (5364 males and 7027 females) and 48,531.09 person-years of observation, a total of 345 cancers were identified. Significantly increased SIRs were observed for prostate cancer in male patients, thyroid cancer and breast cancer in female patients and bladder cancers in both male and female patients. Unfortunately, the low incidence rate of certain cancers limited the power of our statistical analyses. This study demonstrated the patterns of malignancies in vitiligo patients of Taiwan. Compared with the general population, male patients had higher risks of prostate cancer and female patients had higher risks of thyroid cancer and breast cancer. The risks of bladder cancer were also increased in both male and female patients.
Suggested Citation
Cheng-Yuan Li & Ying-Xiu Dai & Yi-Ju Chen & Szu-Ying Chu & Tzeng-Ji Chen & Chen-Yi Wu & Chih-Chiang Chen & Ding-Dar Lee & Yun-Ting Chang, 2018.
"Cancer Risks in Vitiligo Patients: A Nationwide Population-Based Study in Taiwan,"
IJERPH, MDPI, vol. 15(9), pages 1-10, August.
Handle:
RePEc:gam:jijerp:v:15:y:2018:i:9:p:1847-:d:166046
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:15:y:2018:i:9:p:1847-:d:166046. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.